Publication: 976

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
      QxMD      Google Scholar   
Citation:
Ann Oncol vol 23 (9) 2356-62
Year:
2012
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
2
Parents:
449   745  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
               
Networks:
 
Study
CALGB-50402
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: